Defense World
08 Feb 2026, 09:16 UTC · 32w ago
Verdict
Headline takes no side. We score HAE +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Haemonetics raised its full-year revenue, earnings, and free cash flow guidance.
More positive than 99% of claims this week
The company experienced "outsized" growth in its NexSys plasma platform and TEG hospital blood management franchise.
So whatStrong growth in core product platforms suggests increasing market share and scalable revenue streams.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 93% of claims this week
Haemonetics continues to see weakness in its Interventional Technologies segment.
More negative than 86% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported strong growth in key platforms and raised full-year revenue, earnings, and free cash flow guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+80.8%
Price agrees with the score
$107.28 vs $59.34 close before publication (Feb 6) · not market-adjusted
HAE chart →
